Bern scientists develop promising hydrogel treatment for melanoma
Applied directly to the area where a tumour is located, a hydrogel developed by researchers at the University of Bern activates the body’s own defence system against melanoma, an aggressive form of skin cancer.
This content was published on
2 minutes
swissinfo.ch/gw
Español
es
Científicos de Berna desarrollan un prometedor tratamiento para el melanoma
The chances of survival among melanoma patients decline when the cancer spreads to other organs. In the last decade, treatments that activate the patient’s immune system with so-called immune checkpoint inhibitors have been successful – but only up to a point.
“Unfortunately, a good half of all patients do not respond” to such treatments, said Mirjam Schenk of the Institute of Pathology.
One particular therapy uses a live bacterium (Bacillus Calmette-Guérin, or BCG) that is not especially effective in patients with metastases (tumour derivates) in their internal organs.
Schenk and her team decided to use components from BCG to develop their heat-sensitive gel and have now shown that in this form, the bacterium can be more effective at controlling tumour growth. The gel they developed together with teams at the Federal Institute of Technology Lausanne (EPFL) and Harbor-UCLA Medical Center in the United States can be easily administered just once. Liquid at room temperature, it becomes viscous at body temperature, so it is able to continually release components of the bacterium. The immune system is thus activated on a sustained basis.
In trials, mice with melanoma showed significantly prolonged survival after treatment with the gel, the University reports on its websiteExternal link. The gel was also able to suppress the formation of metastases in the lungs. The researchers recorded improved immune responses among T cells against melanoma cells in biopsies of melanoma patients who had had BCG therapy.
“Local application of the hydrogel is an effective and safe immunotherapeutic option to reduce metastatic burden and prolong the survival of patients,” said Schenk.
The scientists now plan to conduct clinical trials to test the gel’s efficacy in patients when compared with already approved treatments.
Popular Stories
More
Swiss Politics
Why cars still reign supreme in ‘rail-nation’ Switzerland
Swiss central banker wants to boost equity to head off risks
This content was published on
Equity levels at the Swiss National Bank (SNB) are much too low for the risks its large balance sheet poses, according to Martin Schlegel.
Beer sales in Switzerland watered down by bad weather
This content was published on
The past brewing year fell through in Switzerland, partly due to the bad weather. Beer sales shrank again. For the first time, per capita consumption fell below the 50 liter mark.
Compensation for Syrian after pregnant wife denied help on Swiss train
This content was published on
Switzerland’s Federal Court has partially upheld the appeal of a Syrian family being deported from Switzerland to Italy in 2014. The man now also receives compensation.
Swiss-EU negotiations: Cassis to meet Sefcovic in Bern
This content was published on
Swiss Foreign Minister Ignazio Cassis will meet the Vice-President of the EU Commission, Maros Sefcovic, in Bern on Wednesday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
More Swiss are getting cancer, but fewer are dying from it
This content was published on
The number of cancer patients is increasing, mainly due to the ageing population. But the risk of dying from the disease has decreased.
What’s on the horizon for Swiss research in Europe?
This content was published on
After Switzerland’s exclusion from EU research schemes, the government stepped in with transitional grants and is seeking new research partnerships.
Ukraine war threatens to derail development of new cancer treatments
This content was published on
The war in Ukraine could disrupt hundreds of clinical trials for critical cancer drugs, many of which are being developed by companies in Switzerland.
Science, even in Switzerland, needs more diplomacy and more female researchers
This content was published on
Switzerland is lending a helping hand to scientific diplomacy to tackle future challenges such as pandemics and climate disasters.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.